Compare Amylx Pharmaceuticals Inc (AMLX) vs Western Digital Corp (WDC) Price & Performance

AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.

The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.

Western Digital (WDC) trades at $582.59, up 0.78% on the day, with a neutral technical signal and bullish moving averages. The company has beaten EPS estimates for three consecutive quarters, with Q2 2026 expected at $3.29. Strong profitability metrics include a 55.07% net income margin and 37.73% ROE. Recent news highlights AI-driven storage demand and analyst optimism, including a Wells Fargo price target hike on July 10, 2026.

WDC's outlook is positive due to AI infrastructure tailwinds and consistent earnings beats, but risks include sector volatility and premium valuations. The consensus price target of $610.86 suggests modest upside, supported by 72% analyst buy ratings. Investors should monitor execution against growth forecasts and competitive dynamics in the memory market.